Combining drugs and extending treatment - a PFS end point is not sufficient.

about

Combining drugs and extending treatment - a PFS end point is not sufficient.

Item

http://www.wikidata.org/entity/Q53110057

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Combining drugs and extending treatment - a PFS end point is not sufficient.

@en

Combining drugs and extending treatment - a PFS end point is not sufficient.

@nl

type

Item

label

Combining drugs and extending treatment - a PFS end point is not sufficient.

@en

Combining drugs and extending treatment - a PFS end point is not sufficient.

@nl

prefLabel

Combining drugs and extending treatment - a PFS end point is not sufficient.

@en

Combining drugs and extending treatment - a PFS end point is not sufficient.

@nl

P1476

Combining drugs and extending treatment - a PFS end point is not sufficient.

@en

P2093

Vinay Prasad

http://www.w3.org/2001/XMLSchema#string

P2860

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.

Progression-free survival: meaningful or simply measurable?

Routine Cancer Antigen 125 Surveillance-The Fatal Attraction of Testing.

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

P304

521-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2017.72

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bishal Gyawali

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28534528

http://www.w3.org/2001/XMLSchema#string